Previous studies have demonstrated the efficiency of HDAC inhibitors in reducing cardiac hypertrophy under pathological conditions [33,34] and in attenuating structural remodelling after myocardial infarction [35]. This evidence concerns the gene HDAC9 and myocardial infarction.